[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100591414":3},{"organization":4,"outcomesModule":7,"designInfo":38,"detailedDescription":11,"studyPopulation":11,"armGroups":44,"interventions":50,"overallOfficials":11,"centralContacts":55,"locations":61,"responsibleParty":145,"collaborators":11,"id":147,"slug":148,"hasResults":149,"nctId":150,"briefTitle":151,"officialTitle":152,"acronym":11,"eligibilityCriteria":153,"healthyVolunteers":149,"sex":154,"minAge":155,"maxAge":11,"enrollmentInfo":156,"targetDuration":11,"studyType":159,"phases":160,"briefSummary":162,"conditions":163,"keywords":171,"overallStatus":64,"whyStopped":11,"lastUpdateSubmitDate":175,"lastUpdatePostDateStruct":176,"startDateStruct":179,"completionDateStruct":181,"leadSponsor":183,"locationsCount":185},{"fullName":5,"class":6},"Exscientia AI Limited","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":16,"otherOutcomes":11},[9,13],{"measure":10,"description":11,"timeFrame":12},"Number of Participants with Treatment-emergent Adverse Events (TEAEs)",null,"Up to 282 days",{"measure":14,"description":11,"timeFrame":15},"Number of Participants With Dose-limiting toxicities (DLTs)","Up to 28 days",[17,20,22,24,27,29,31,33,35],{"measure":18,"description":11,"timeFrame":19},"Time to Maximum Concentration (Tmax) of EXS73565-001","Up to 253 days",{"measure":21,"description":11,"timeFrame":19},"Area Under the Concentration-time Curve from Time Zero to the Time of the Last Quantifiable Concentration AUC(0-last) of EXS73565-001",{"measure":23,"description":11,"timeFrame":19},"Maximum Concentration (Cmax) of EXS73565-001",{"measure":25,"description":11,"timeFrame":26},"Overall Response Rate (ORR)","Up to 434 days",{"measure":28,"description":11,"timeFrame":26},"Progression Free Survival",{"measure":30,"description":11,"timeFrame":26},"Duration of Response",{"measure":32,"description":11,"timeFrame":26},"Time to Respond",{"measure":34,"description":11,"timeFrame":26},"Time to Progression",{"measure":36,"description":11,"timeFrame":37},"Overall Survival","12 and 24 months",{"allocation":39,"interventionModel":40,"interventionModelDescription":11,"primaryPurpose":41,"observationalModel":11,"timePerspective":11,"maskingInfo":42},"NA","SINGLE_GROUP","TREATMENT",{"masking":43,"maskingDescription":11,"whoMasked":11},"NONE",[45],{"label":46,"type":47,"description":11,"interventionNames":48},"EXS73565","EXPERIMENTAL",[49],"Drug: EXS73565",[51],{"type":52,"name":46,"description":53,"armGroupLabels":54,"otherNames":11},"DRUG","EXS73565 oral administration",[46],[56],{"name":57,"role":58,"phone":59,"phoneExt":11,"email":60},"Exscientia AI Ltd.","CONTACT","385-374-1724","clinicaltrials@recursion.com",[62,75,86,97,102,107,116,127,137],{"facility":63,"status":64,"city":65,"state":11,"zip":66,"country":67,"countryCode":68,"cosmosGeoPoint":69,"geoPoint":74,"contacts":11},"LLC ARENSIA Exploratory Medicine","RECRUITING","Tbilisi","119","Georgia","GE",{"type":70,"coordinates":71},"Point",[72,73],44.83412,41.69143,{"lat":73,"lon":72},{"facility":76,"status":64,"city":77,"state":11,"zip":78,"country":79,"countryCode":80,"cosmosGeoPoint":81,"geoPoint":85,"contacts":11},"IMSP Institute of Oncology, ARENSIA Exploratory Medicine","Chisinau","MD-2025","Moldova","MD",{"type":70,"coordinates":82},[83,84],28.85938,47.00902,{"lat":84,"lon":83},{"facility":87,"status":64,"city":88,"state":11,"zip":89,"country":90,"countryCode":91,"cosmosGeoPoint":92,"geoPoint":96,"contacts":11},"Hospital Beata Maria Ana","Madrid","28007","Spain","ES",{"type":70,"coordinates":93},[94,95],-3.70256,40.4165,{"lat":95,"lon":94},{"facility":98,"status":64,"city":88,"state":11,"zip":11,"country":90,"countryCode":91,"cosmosGeoPoint":99,"geoPoint":101,"contacts":11},"Hospital Fundación Jiménez Diaz",{"type":70,"coordinates":100},[94,95],{"lat":95,"lon":94},{"facility":103,"status":64,"city":88,"state":11,"zip":11,"country":90,"countryCode":91,"cosmosGeoPoint":104,"geoPoint":106,"contacts":11},"Hospital Universitario HM Sanchinarro",{"type":70,"coordinates":105},[94,95],{"lat":95,"lon":94},{"facility":108,"status":64,"city":109,"state":11,"zip":110,"country":90,"countryCode":91,"cosmosGeoPoint":111,"geoPoint":115,"contacts":11},"Clinica Universidad de Navarra","Pamplona","31008",{"type":70,"coordinates":112},[113,114],-1.64323,42.81687,{"lat":114,"lon":113},{"facility":117,"status":64,"city":118,"state":11,"zip":119,"country":120,"countryCode":121,"cosmosGeoPoint":122,"geoPoint":126,"contacts":11},"Medical Center of LLC ARENSIA Exploratory Medicine","Kyiv","01135","Ukraine","UA",{"type":70,"coordinates":123},[124,125],30.5238,50.45466,{"lat":125,"lon":124},{"facility":128,"status":64,"city":129,"state":11,"zip":11,"country":130,"countryCode":131,"cosmosGeoPoint":132,"geoPoint":136,"contacts":11},"St James's University Hospital","Leeds","United Kingdom","UK",{"type":70,"coordinates":133},[134,135],-1.54785,53.79648,{"lat":135,"lon":134},{"facility":138,"status":64,"city":139,"state":11,"zip":11,"country":130,"countryCode":131,"cosmosGeoPoint":140,"geoPoint":144,"contacts":11},"University Hospitals Plymouth NHS Trust (Derriford Hospital)","Plymouth",{"type":70,"coordinates":141},[142,143],-4.14305,50.37153,{"lat":143,"lon":142},{"type":146,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100591414","phase-1-dose-determining-study-of-exs73565-in-participants-with-relapsed-or-refractory-b-cell-malignancies-100591414",false,"NCT06980116","Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell Malignancies","A Phase 1 Open-label, Multicenter, Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of EXS73565 in Participants With Relapsed or Refractory B-cell Malignancies","Key Inclusion Criteria:\n\n* Age ≥18 years at the time of signing the informed consent.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.\n* Histologically confirmed diagnosis of one of the following B-cell malignancies: chronic lymphocytic leukemia (CLL), including Richter's transformation from CLL, mantle-cell lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, marginal zone lymphoma, or waldenström macroglobulinaemia.\n* Participants that have relapsed after standard of care or have progressed during standard of care or are not suitable for standard of care therapy\n\nKey Exclusion Criteria:\n\n* Any medical or psychiatric condition that, in the view of the Principal Investigator, could jeopardize or would compromise the participant's safety or ability to participate in the study.\n* Known central nervous system (CNS) malignancy or primary CNS lymphoma.\n* Concurrent active or previous malignancy (other than the primary lymphoma\u002FCLL for which the participant will be treated on this protocol within 5 years prior to randomization; participants with prior cancers may be enrolled with documented Sponsor approval.\n* Received anticancer therapy, including chemotherapy, immunotherapy, radiation therapy (with the exception of palliative radiotherapy), biologic therapy, cancer-related hormonal therapy, or any investigational therapy within 14 days or 5 half-lives (whichever is shorter) before the first dose of the study treatment.","ALL","18 Years",{"count":157,"type":158},85,"ESTIMATED","INTERVENTIONAL",[161],"PHASE1","The purpose of this study is to characterize the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of EXS73565 administered orally as a single agent in participants with relapsed\u002Frefractory B-cell malignancies.",[164,165,166,167,168,169,170],"Relapsed or Refractory B-cell Malignancies","Chronic Lymphocytic Leukemia\u002FSmall Lymphocytic Lymphoma (CLL\u002FSLL)","Follicular Lymphoma (FL)","Marginal Zone Lymphoma (MZL)","Mantle Cell Lymphoma (MCL)","Diffuse-large B-cell Lymphoma (DLBCL)","Waldenstrom's Macroglobulinemia (WM)",[172,173,166,167,168,169,170,174],"B-cell Malignancies","Chronic lymphocytic leukemia\u002Fsmall lymphocytic lymphoma (CLL\u002FSLL)","MALT1","2026-06-09",{"date":177,"type":178},"2026-06-11","ACTUAL",{"date":180,"type":178},"2025-03-31",{"date":182,"type":158},"2028-12",{"name":184,"class":6},"Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.",9]